(Q38188582)

30 August 2017

title

Review of angiogenesis in hepatocellular carcinoma (English)

1 reference

30 August 2017

1 reference

4

Yoshihiko Maehara

1 reference

30 August 2017

Jun Muto

1

1 reference

30 August 2017

Ken Shirabe

series ordinal

2

1 reference

30 August 2017

Keishi Sugimachi

series ordinal

3

1 reference

30 August 2017

publication date

2 April 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

45

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

1-9

1 reference

Global cancer statistics, 2002

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Epidemiology of hepatocellular carcinoma in Japan and Korea. A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Systemic treatment of hepatocellular carcinoma: dawn of a new era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

The current status of imaging diagnosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

HCC and angiogenesis: possible targets and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hepatic resection for hepatocellular carcinoma based on tumor hemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hepatocellular carcinoma: current management and future trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Arteriogenesis versus angiogenesis: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Down-regulation of artery in moderately differentiated hepatocellular carcinoma related to tumor development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

CT during hepatic arteriography and portography: an illustrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Oxygen: modulator of metabolic zonation and disease of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hypoxia and hypoxia inducible factors: diverse roles in liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vascular changes in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

HIF1 and oxygen sensing in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiopoietin and Tie signaling pathways in vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiogenesis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Structure and function of VEGF/VEGF-receptor system involved in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

The role of nitric oxide in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiogenesis in chronic liver disease and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

The potential of angiogenesis soluble markers in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vascular normalization as an emerging strategy to enhance cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Targeting the ANGPT-TIE2 pathway in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Regulation and targets of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

Medical therapies for hepatocellular carcinoma: a critical view of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12310

21 January 2018

Identifiers

DOI

10.1111/HEPR.12310

1 reference

30 August 2017

1 reference